Insmed Q1 ARIKAYCE revenue $75.5M (+16%); TPIP PH-ILD shows strong clinical worsening signal

INSMED Inc

2024-Q1 EPS reported -$1.06 revenue$75,500,000

ARIKAYCE Q1 revenue $75.5M, up 16% YoY; net loss $157.1M ($1.06/share) vs $159.8M ($1.17) prior year.
TPIP Phase 2 PH-ILD: 79.3% reached max 640µg dose; clinical worsening 10.3% vs 50% placebo (p=0.0164).
TPIP Phase 2 PAH blinded: first 40 patients showed mean PVR reduction 19.9%, 6MWD +43 meters.
Brensocatib ASPEN topline data expected latter part of Q2 2024; 2024 ARIKAYCE guidance $340M-$360M.
Cash $595.7M at March 31, 2024; company plans Phase 3 for TPIP in PH-ILD in 2025.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INSMED Inc updated its the first quarter ended March 31, 2024 guidance (reaffirmed).

Period: the first quarter ended March 31, 2024
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 9, 2024, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the three months ended March 31, 2024.

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

INSMED Inc filing history →

Source: SEC EDGAR

accession 0001140361-24-025047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.